Essential Reads: Who is at Risk for Depression During the Perimenopause?
Although most women transition to menopause without experiencing psychiatric problems, an estimated 20% experience depression at some point during the menopausal transition.
Although most women transition to menopause without experiencing psychiatric problems, an estimated 20% experience depression at some point during the menopausal transition.
This review discusses the novel neurosteroid antidepressant brexanolone for the treatment of postpartum depression.
This clinical cohort study showed no impact of prenatal lithium exposure on cognitive functioning in children 6 to 14 years of age.
In a webinar put together by 2020 Mom, presenters provide an overview of maternal suicide, review risk factors for suicide in this population, and discuss efforts to generate accurate data on maternal suicide.
In a recent article, Margaret Spinelli, MD describes a proposal to the DSM-V committee of the American Psychiatric Association in 2020 arguing for the inclusion of postpartum psychosis as a unique diagnosis...
Neuroactive steroids, derivatives of allopregnanolone, may be effective for the treatment of premenstrual dysphoric disorder.
Given limited data on the reproductive safety of oxcarbazepine, we would recommend using alternate medications during pregnancy, when possible.
In terms of the efficacy of bright light therapy for depression during pregnancy, the jury is still out.
Our information on the use of medications for smoking cessation in nursing mothers is limited.
Electroconvulsive therapy (ECT) is a safe and effective treatment for many psychiatric illnesses occurring during pregnancy.